Home > Cardiology > HFA 2022 > FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status

FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status

Presented By
Prof. Gerasimos Filippatos, Attikon University Hospital, Greece
Conference
HFA 2022
Trial
FIDELITY
Finerenone demonstrated cardiorenal benefits across the complete spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of left ventricular hypertrophy (LVH) status at baseline. The data of the FIDELITY analysis suggest that patients with LVH may benefit more from the use of finerenone than patients without LVH concerning their risk of HF hospitalisation [1]. Finerenone is a novel, selective, non-steroidal mineralocorticoid receptor antagonist (MRA), which has demonstrated cardiovascular and renal benefits in patients with CKD and T2D in the FIDELIO-DKD (NCT02540993) and FIGARO-DKD trials (NCT02545049) [2,3]. The current FIDELITY analysis included 13,171 patients from both of these trials to assess the efficacy of finerenone on card...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on